IMUX | Immunic, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.5300 - 1.6200
52 Week Range	0.9450 - 1.9200
Beta	1.82
Implied Volatility	177.33%
IV Rank	26.80%
Day's Volume	709,062
Average Volume	313,024
Shares Outstanding	90,079,000
Market Cap	144,126,400
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-04-17

Valuation
Profitability
Growth
Health
P/E Ratio	-1.07
Forward P/E Ratio	N/A
EPS	-1.50
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	85
Country	USA
Website	IMUX

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

IMUX's peers: BCRX, GBIO, KRON, ERAS, CCCC, EWTX, FHTX, STTK, GLUE, KYMR, NRIX, KZR, SPRB, EYEN

*Chart delayed

Analyzing fundamentals for IMUX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see IMUX Fundamentals page.

Watching at IMUX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on IMUX Technicals page.